Total Payments
$15,686
2024 Payments
$11,520
Companies
26
Transactions
267
Medicare Patients
8,296
Medicare Billing
$546,100
Payment Breakdown by Category
Other$10,364 (66.1%)
Food & Beverage$5,098 (32.5%)
Travel$199.45 (1.3%)
Education$24.07 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $10,364 | 5 | 66.1% |
| Food and Beverage | $5,098 | 258 | 32.5% |
| Travel and Lodging | $199.45 | 1 | 1.3% |
| Education | $24.07 | 3 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Pharmaceuticals, Inc | $11,410 | 46 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $918.59 | 63 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $504.28 | 22 | $0 (2024) |
| Merck Sharp & Dohme LLC | $446.33 | 19 | $0 (2024) |
| PFIZER INC. | $307.75 | 22 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $283.19 | 16 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $237.40 | 9 | $0 (2024) |
| ZOLL Medical Corporation | $236.41 | 1 | $0 (2017) |
| Amgen Inc. | $188.57 | 10 | $0 (2024) |
| Amarin Pharma Inc. | $155.71 | 11 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $11,520 | 61 | Janssen Pharmaceuticals, Inc ($10,612) |
| 2023 | $631.74 | 34 | Merck Sharp & Dohme LLC ($85.65) |
| 2022 | $687.95 | 38 | Merck Sharp & Dohme LLC ($171.12) |
| 2021 | $386.28 | 18 | Janssen Pharmaceuticals, Inc ($153.99) |
| 2020 | $250.85 | 15 | Janssen Pharmaceuticals, Inc ($60.98) |
| 2019 | $378.64 | 22 | Novartis Pharmaceuticals Corporation ($195.36) |
| 2018 | $476.92 | 27 | Novartis Pharmaceuticals Corporation ($106.80) |
| 2017 | $1,354 | 52 | Janssen Pharmaceuticals, Inc ($345.71) |
All Payment Transactions
267 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $11.98 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/05/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $14.14 | General |
| Category: Diabetes | ||||||
| 11/25/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $26.95 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/22/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $22.70 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/19/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $16.81 | General |
| Category: Cardiology | ||||||
| 11/13/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $13.71 | General |
| Category: Cardiovascular | ||||||
| 11/12/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $22.33 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/12/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $16.09 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 10/30/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $23.36 | General |
| Category: DIABETES | ||||||
| 10/22/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $12.72 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/16/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $16.53 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/09/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $18.33 | General |
| Category: Diabetes | ||||||
| 09/27/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $32.86 | General |
| Category: DIABETES | ||||||
| 09/25/2024 | LANTHEUS MEDICAL IMAGING, INC. | DEFINITY (Drug) | Food and Beverage | In-kind items and services | $20.17 | General |
| Category: CONTRAST AGENT | ||||||
| 09/24/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $22.58 | General |
| Category: Not Applicable | ||||||
| 09/20/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,399.00 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 09/19/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $23.32 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/13/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $8.83 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/11/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $20.12 | General |
| Category: Not Applicable | ||||||
| 08/30/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $8.67 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/22/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Travel and Lodging | Cash or cash equivalent | $199.45 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 08/19/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,030.00 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 08/19/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $11.20 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/14/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $20.37 | General |
| Category: Diabetes | ||||||
| 08/07/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $20.82 | General |
| Category: CARDIOVASCULAR | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 27 | 2,203 | 2,615 | $470,839 | $135,484 |
| 2022 | 25 | 2,291 | 2,643 | $507,330 | $141,122 |
| 2021 | 23 | 2,021 | 2,398 | $415,230 | $141,295 |
| 2020 | 21 | 1,781 | 2,109 | $382,640 | $128,198 |
Total Patients
8,296
Total Services
9,765
Medicare Billing
$546,100
Procedure Codes
108
All Medicare Procedures & Services
108 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 328 | 462 | $94,710 | $45,638 | 48.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 151 | 216 | $32,400 | $13,949 | 43.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 72 | 74 | $22,200 | $10,523 | 47.4% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 166 | 168 | $76,440 | $9,032 | 11.8% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 142 | 142 | $64,610 | $7,205 | 11.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 51 | 61 | $12,200 | $5,820 | 47.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 48 | 48 | $13,200 | $5,128 | 38.9% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 84 | 84 | $25,200 | $5,010 | 19.9% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 18 | 24 | $10,824 | $4,200 | 38.8% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 291 | 317 | $25,360 | $3,653 | 14.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 30 | 30 | $8,100 | $3,583 | 44.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 23 | 24 | $6,960 | $3,551 | 51.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 51 | 52 | $7,540 | $3,292 | 43.7% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 253 | 334 | $10,020 | $2,118 | 21.1% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2023 | 79 | 113 | $10,170 | $1,961 | 19.3% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 54 | 74 | $7,400 | $1,682 | 22.7% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Office | 2023 | 83 | 83 | $5,810 | $1,383 | 23.8% |
| 93351 | Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | Facility | 2023 | 18 | 18 | $7,200 | $1,135 | 15.8% |
| 93295 | Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | Office | 2023 | 26 | 41 | $8,610 | $1,046 | 12.2% |
| 93312 | Ultrasound of heart with probe in esophagus, with report | Facility | 2023 | 11 | 11 | $3,630 | $917.65 | 25.3% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Office | 2023 | 83 | 83 | $3,735 | $916.11 | 24.5% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 11 | 12 | $2,280 | $776.28 | 34.0% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2023 | 11 | 11 | $3,300 | $679.91 | 20.6% |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | Office | 2023 | 12 | 19 | $1,425 | $608.57 | 42.7% |
| 93298 | Evaluation of cardiac rhythm monitor system, remote up to 30 days | Office | 2023 | 11 | 18 | $1,440 | $384.30 | 26.7% |
About Dr. Michael Adenaike, MD
Dr. Michael Adenaike, MD is a Internal Medicine healthcare provider based in Doylestown, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/08/2008. The National Provider Identifier (NPI) number assigned to this provider is 1700049939.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Adenaike, MD has received a total of $15,686 in payments from pharmaceutical and medical device companies, with $11,520 received in 2024. These payments were reported across 267 transactions from 26 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($10,364).
As a Medicare-enrolled provider, Adenaike has provided services to 8,296 Medicare beneficiaries, totaling 9,765 services with total Medicare billing of $546,100. Data is available for 4 years (2020–2023), covering 108 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Cardiovascular Disease
- Location Doylestown, PA
- Active Since 07/08/2008
- Last Updated 03/08/2023
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1700049939
Products in Payments
- XARELTO (Drug) $11,410
- ELIQUIS (Drug) $689.70
- ENTRESTO (Drug) $600.77
- VERQUVO (Drug) $446.33
- LEQVIO (Drug) $317.82
- JARDIANCE (Drug) $237.40
- Repatha (Biological) $170.06
- BRILINTA (Drug) $165.55
- Vascepa (Drug) $155.71
- Visia AF (Device) $118.01
- FARXIGA (Drug) $117.64
- Arcalyst (Drug) $117.24
- MULTAQ (Drug) $106.79
- CHANTIX (Drug) $91.93
- Definity (Drug) $72.10
- LifeVest (Device) $57.97
- NORTHERA (Drug) $56.58
- Ozempic (Drug) $52.84
- AMPLATZER Occluders (Device) $48.34
- PRALUENT (Drug) $40.09
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Doylestown
Dr. Mustafa Noor, M.d, M.D
Internal Medicine — Payments: $172,302
Internal Medicine $172,302
Dr. Luis Arzeno Tejada, M.d, M.D
Internal Medicine — Payments: $13,067
Internal Medicine $13,067
Dr. Richard Kondan, Do, DO
Internal Medicine — Payments: $10,318
Internal Medicine $10,318
Dr. Kiley Walp, D.o, D.O
Internal Medicine — Payments: $9,617
Internal Medicine $9,617
Austin Liu, Md, MD
Internal Medicine — Payments: $8,344
Internal Medicine $8,344
Oleg Vinnikov, Md, MD
Internal Medicine — Payments: $6,126
Internal Medicine $6,126